1/21/2025

Janusmed fosterpåverkan

Janusmed fosterpåverkan – Viekirax

Janusmed fosterpåverkan tillhandahåller bedömningar av eventuella risker för fostret, när en gravid kvinna använder olika läkemedel. Observera att texterna är generella, och att en bedömning måste göras i varje enskilt fall. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed fosterpåverkan och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Ritonavir

Ritonavir

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Veroniki AA, Antony J, Straus SE, Ashoor HM, Finkelstein Y, Khan PA et al. Comparative safety and effectiveness of perinatal antiretroviral therapies for HIV-infected women and their children: Systematic review and network meta-analysis including different study designs. PLoS One. 2018;13(6):e0198447.

  2. Williams PL, Crain MJ, Yildirim C, Hazra R, Van Dyke RB, Rich K et al. Congenital anomalies and in utero antiretroviral exposure in human immunodeficiency virus-exposed uninfected infants. JAMA Pediatr. 2015;169(1):48-55.

  3. Sibiude J, Mandelbrot L, Blanche S, Le Chenadec J, Boullag-Bonnet N, Faye A et al. Association between prenatal exposure to antiretroviral therapy and birth defects: an analysis of the French perinatal cohort study (ANRS CO1/CO11). PLoS Med. 2014;11(4):e1001635.

  4. Alemu FM, Yalew AW. Does antiretroviral therapy cause congenital malformations? A systematic review and meta-analysis. Epidemiol Health. 2021;43:e2021008.

  5. Saint-Lary L, Benevent J, Damase-Michel C, Vayssière C, Leroy V, Sommet A. Adverse perinatal outcomes associated with prenatal exposure to protease-inhibitor-based versus non-nucleoside reverse transcriptase inhibitor-based antiretroviral combinations in pregnant women with HIV infection: a systematic review and meta-analysis. BMC Pregnancy Childbirth. 2023;23(1):80.

  6. Cowdell I, Beck K, Portwood C, Sexton H, Kumarendran M, Brandon Z et al. Adverse perinatal outcomes associated with protease inhibitor-based antiretroviral therapy in pregnant women living with HIV: A systematic review and meta-analysis. EClinicalMedicine. 2022;46:101368.

  7. Sirois PA, Huo Y, Williams PL, Malee K, Garvie PA, Kammerer B et al. Safety of perinatal exposure to antiretroviral medications: developmental outcomes in infants. Pediatr Infect Dis J. 2013;32(6):648-55.

  8. Wedderburn CJ, Weldon E, Bertran-Cobo C, Rehman AM, Stein DJ, Gibb DM et al. Early neurodevelopment of HIV-exposed uninfected children in the era of antiretroviral therapy: a systematic review and meta-analysis. Lancet Child Adolesc Health. 2022;6(6):393-408.

  9. Caniglia EC, Patel K, Huo Y, Williams PL, Kapetanovic S, Rich KC et al. Atazanavir exposure in utero and neurodevelopment in infants: a comparative safety study. AIDS. 2016;30(8):1267-78.

  10. Rowe K, Buivydaite R, Heinsohn T, Rahimzadeh M, Wagner RG, Scerif G et al. Executive function in HIV-affected children and adolescents: a systematic review and meta-analyses. AIDS Care. 2021;33(7):833-857.

  11. TERIS (The Teratogen Information System). Ritonavir. Micromedex [www]. [cited 2025-01-13].

  12. The Antiretroviral Pregnancy Registry Interim Report. The Antiretroviral Pregnancy Registry [www]. [updated 2024-06-01, cited 2024-09-25].

  13. Van Dyke RB, Chadwick EG, Hazra R, Williams PL, Seage GR. The PHACS SMARTT Study: Assessment of the Safety of In Utero Exposure to Antiretroviral Drugs. Front Immunol. 2016;7:199.

  14. Garneau WM, Jones-Beatty K, Ufua MO, Mostafa HH, Klein SL, Burd I et al. Analysis of Clinical Outcomes of Pregnant Patients Treated With Nirmatrelvir and Ritonavir for Acute SARS-CoV-2 Infection. JAMA Netw Open. 2022;5(11):e2244141.

  15. Loza A, Farias R, Gavin N, Wagner R, Hammer E, Shields A. Short-term Pregnancy Outcomes After Nirmatrelvir-Ritonavir Treatment for Mild-to-Moderate Coronavirus Disease 2019 (COVID-19). Obstet Gynecol. 2022;140(3):447-449.

  16. EMA. Paxlovir Public Assessment Report. EMA [www]. [updated 2021-12-16, cited 2025-01-13].

  17. Catlin NR, Bowman CJ, Campion SN, Cheung JR, Nowland WS, Sathish JG et al. Reproductive and developmental safety of nirmatrelvir (PF-07321332), an oral SARS-CoV-2 M. Reprod Toxicol. 2022;108(0):56-61.

  1. Veroniki AA, Antony J, Straus SE, Ashoor HM, Finkelstein Y, Khan PA et al. Comparative safety and effectiveness of perinatal antiretroviral therapies for HIV-infected women and their children: Systematic review and network meta-analysis including different study designs. PLoS One. 2018;13(6):e0198447.
  2. Williams PL, Crain MJ, Yildirim C, Hazra R, Van Dyke RB, Rich K et al. Congenital anomalies and in utero antiretroviral exposure in human immunodeficiency virus-exposed uninfected infants. JAMA Pediatr. 2015;169(1):48-55.
  3. Sibiude J, Mandelbrot L, Blanche S, Le Chenadec J, Boullag-Bonnet N, Faye A et al. Association between prenatal exposure to antiretroviral therapy and birth defects: an analysis of the French perinatal cohort study (ANRS CO1/CO11). PLoS Med. 2014;11(4):e1001635.
  4. Alemu FM, Yalew AW. Does antiretroviral therapy cause congenital malformations? A systematic review and meta-analysis. Epidemiol Health. 2021;43:e2021008.
  5. Saint-Lary L, Benevent J, Damase-Michel C, Vayssière C, Leroy V, Sommet A. Adverse perinatal outcomes associated with prenatal exposure to protease-inhibitor-based versus non-nucleoside reverse transcriptase inhibitor-based antiretroviral combinations in pregnant women with HIV infection: a systematic review and meta-analysis. BMC Pregnancy Childbirth. 2023;23(1):80.
  6. Cowdell I, Beck K, Portwood C, Sexton H, Kumarendran M, Brandon Z et al. Adverse perinatal outcomes associated with protease inhibitor-based antiretroviral therapy in pregnant women living with HIV: A systematic review and meta-analysis. EClinicalMedicine. 2022;46:101368.
  7. Sirois PA, Huo Y, Williams PL, Malee K, Garvie PA, Kammerer B et al. Safety of perinatal exposure to antiretroviral medications: developmental outcomes in infants. Pediatr Infect Dis J. 2013;32(6):648-55.
  8. Wedderburn CJ, Weldon E, Bertran-Cobo C, Rehman AM, Stein DJ, Gibb DM et al. Early neurodevelopment of HIV-exposed uninfected children in the era of antiretroviral therapy: a systematic review and meta-analysis. Lancet Child Adolesc Health. 2022;6(6):393-408.
  9. Caniglia EC, Patel K, Huo Y, Williams PL, Kapetanovic S, Rich KC et al. Atazanavir exposure in utero and neurodevelopment in infants: a comparative safety study. AIDS. 2016;30(8):1267-78.
  10. Rowe K, Buivydaite R, Heinsohn T, Rahimzadeh M, Wagner RG, Scerif G et al. Executive function in HIV-affected children and adolescents: a systematic review and meta-analyses. AIDS Care. 2021;33(7):833-857.
  11. TERIS (The Teratogen Information System). Ritonavir. Micromedex [www]. [cited 2025-01-13].
  12. The Antiretroviral Pregnancy Registry Interim Report. The Antiretroviral Pregnancy Registry [www]. [updated 2024-06-01, cited 2024-09-25].
  13. Van Dyke RB, Chadwick EG, Hazra R, Williams PL, Seage GR. The PHACS SMARTT Study: Assessment of the Safety of In Utero Exposure to Antiretroviral Drugs. Front Immunol. 2016;7:199.
  14. Garneau WM, Jones-Beatty K, Ufua MO, Mostafa HH, Klein SL, Burd I et al. Analysis of Clinical Outcomes of Pregnant Patients Treated With Nirmatrelvir and Ritonavir for Acute SARS-CoV-2 Infection. JAMA Netw Open. 2022;5(11):e2244141.
  15. Loza A, Farias R, Gavin N, Wagner R, Hammer E, Shields A. Short-term Pregnancy Outcomes After Nirmatrelvir-Ritonavir Treatment for Mild-to-Moderate Coronavirus Disease 2019 (COVID-19). Obstet Gynecol. 2022;140(3):447-449.
  16. EMA. Paxlovir Public Assessment Report. EMA [www]. [updated 2021-12-16, cited 2025-01-13].
  17. Catlin NR, Bowman CJ, Campion SN, Cheung JR, Nowland WS, Sathish JG et al. Reproductive and developmental safety of nirmatrelvir (PF-07321332), an oral SARS-CoV-2 M. Reprod Toxicol. 2022;108(0):56-61.
2 2
2 2

Ombitasvir

Ombitasvir

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. EMA. Viekirax. Public Assessment Report 2014-11-20. https://goo.gl/cLRXqZ

  1. EMA. Viekirax. Public Assessment Report 2014-11-20. https://goo.gl/cLRXqZ
2 2
2 2

Paritaprevir

Paritaprevir

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. EMA. Viekirax. Public Assessment Report 2014-11-20. https://goo.gl/cLRXqZ

  1. EMA. Viekirax. Public Assessment Report 2014-11-20. https://goo.gl/cLRXqZ